| Literature DB >> 35935404 |
Yi Guo1, Xianmei Yang2, Dan Wang2, Ruoxin Fan2, Yiying Liang1, Rongke Wang2, Hu Xiang2, Yuanyuan Liu1, Xiang Liu3.
Abstract
Background: Violence to others (hereinafter referred to as "violence-TO") is common in individuals with schizophrenia. The reported prevalence of violence-TO among schizophrenics ranges widely in existing studies. Improved prevalence estimates and identification of moderators are needed to guide future management and research.Entities:
Keywords: meta-analysis; prevalence; schizophreina; spatial distribution; violence
Year: 2022 PMID: 35935404 PMCID: PMC9354073 DOI: 10.3389/fpsyt.2022.939329
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 5.435
FIGURE 1Study selection.
Characteristics of studies included in the meta-analysis.
| References | Research time | Study site | Study type | Coastal area | Economic circle | Diagnostic criteria | Patient source | Sample size ( | Male ( | Age (year) | Type of violence | Quality assessment |
| Sha et al. ( | NA | Yangzhou, Jiangsu | CS | No | Yes | CCMD-2 | Inpatient | 80 | 80 | 45.16 | I | 7 |
| Gan and Lv ( | NA | Jinan, Shandong | CS | No | No | CCMD-2 | Inpatient | 125 | 92 | 28.20 | I | 7 |
| Zhou ( | NA | Nanchong, Sichuan | CS | No | No | CCMD-2 | Inpatient | 141 | NA | NA | II | 4 |
| Cui et al. ( | 1994.5–1996.4 | Jinan, Shandong | CS | No | No | CCMD-2 | Inpatient | 1,030 | 607 | 31.90 | III | 7 |
| Ma and Hu ( | 1990.6–1997.5 | Jiamusi, Heilongjiang | CS | No | No | DSM-II | Inpatient | 280 | 161 | NA | II | 5 |
| Wang and Yan ( | 1996.8–2000.2 | Zibo, Shandong | CS | No | No | CCMD-2 | Inpatient | 1,018 | NA | NA | III | 4 |
| Lv et al. ( | 2001.3 | Luoyang, Henan | CS | No | No | CCMD-2 | Inpatient | 188 | 143 | 34.24 | I | 7 |
| Zhang et al. ( | NA | Jining, Shandong | CS | No | No | CCMD-2 | Inpatient | 149 | NA | NA | II | 4 |
| Li ( | 1999.6–1999.8 | Xinxiang, Henan | CS | No | No | CCMD-2 | Inpatient | 58 | 0 | 30.79 | I, II, III | 7 |
| Li and Zhou ( | 1970.9–2002.1 | Xiamen, Fujian | CS | Yes | No | CCMD-3 | Inpatient | 386 | 303 | 42.40 | III, IV | 7 |
| Chen and Huang ( | 2003.9–2003.11 | Longquan, Guangxi | CS | No | No | CCMD-3 | Inpatient | 147 | 147 | 30.60 | I, III | 5 |
| Zhu and Wang ( | 1998.1–2003.1 | Hohhot, Inner Mongolia | CS | No | No | CCMD-3 | Inpatient | 215 | 136 | 28.00 | I | 6 |
| Gao et al. ( | 2004.1–2004.12 | Beijing | CS | No | Yes | CCMD-3 | Inpatient | 106 | 106 | 30.60 | III | 7 |
| Li et al. ( | 2005.1–2005.10 | Beijing | CS | No | Yes | CCMD-3 | Inpatient | 148 | 148 | NA | II, III | 4 |
| Zhang and Li ( | NA | Beijing | CS | No | Yes | CCMD-3 | Inpatient | 92 | 77 | 42.58 | IV | 4 |
| Xiong et al. ( | 2005.7–2006.11 | Zigong, Sichuan | CS | No | No | CCMD-3 | Inpatient | 158 | 98 | 36.51 | I, II | 7 |
| Guo ( | 2003.1–2003.12 | Luoyang, Henan | CS | No | No | CCMD-3 | Inpatient | 193 | 102 | 25.35 | I | 6 |
| Ran et al. ( | 1994.1–2008.1 | Chengdu, Sichuan | C | No | No | ICD-10 | Non-inpatient | 489 | 224 | 44.79 | I, III, IV | 7 |
| Ou et al. ( | NA | Minqing, Fujian | CS | No | No | CCMD-3 | Non-inpatient | 1,067 | NA | NA | I | 7 |
| Sun et al. ( | 2006.1–2008.12 | Yantai, Shandong | CS | Yes | No | CCMD-3 | Inpatient | 195 | 121 | 44.00 | III | 6 |
| Gong et al. ( | 2010.3–2010.5 | Guangzhou, Guangdong | CS | Yes | Yes | CCMD-3 | Non-inpatient | 636 | NA | NA | I | 7 |
| Wang et al. ( | NA | Huizhou, Guangzhou | CS | Yes | Yes | CCMD-3 | Non-inpatient | 919 | NA | NA | I | 7 |
| Wei et al. ( | 2009.11–2011.3 | Guangzhou, Guangdong | CS | Yes | Yes | CCMD-3 | Inpatient | 40 | 25 | 24.13 | III | 7 |
| Xiong et al. ( | 2006.10–2009.10 | Chengdu, Sichuan | CS | No | No | ICD-10 | Non-inpatient | 307 | 227 | 36.20 | I | 7 |
| Yang ( | 2009.1–2009.12 | Luoyang, Henan | CS | No | No | CCMD-3 | Inpatient | 196 | 104 | 32.18 | I | 5 |
| Pan et al. ( | 2002.1–2011.1 | Liaocheng, Shandong | CS | No | No | CCMD-3 | Inpatient | 500 | 269 | NA | I, IV | 6 |
| Liang and Liu ( | NA | Nanning, Guangxi | CS | No | No | CCMD-3 | Non-inpatient | 601 | NA | NA | I | 7 |
| Zhang et al. ( | 2011.10–2012.3 | Shantou, Guangdong | CS | Yes | No | CCMD-3 | Non-inpatient | 426 | 264 | 34.48 | I | 7 |
| Song et al. ( | 2011.9–2012.11 | Foshan, Guangdong | CS | No | Yes | CCMD-3 | Non-inpatient | 2,333 | NA | NA | I | 7 |
| Liu et al. ( | 2012.3–2012.9 | Yinchuan, Ningxia | CS | No | No | ICD-10 | Inpatient | 194 | 115 | NA | I | 5 |
| Chen et al. ( | NA | Gaoxiong, Taiwan | C | Yes | NA | DSM-IV | Inpatient | 107 | 33 | 33.40 | I, II | 9 |
| Xia ( | 2010.1–2013.6 | Zhenjiang, Jiangsu | CS | No | Yes | CCMD-3 | Inpatient | 48 | 35 | 35.12 | II | 4 |
| Lang et al. ( | 2010.1–2013.1 | Shizuishan, Ningxia | CS | No | No | CCMD-3 | Non-inpatient | 380 | NA | NA | I | 6 |
| Zhang et al. ( | NA | Kunming, Yunnan | CS | No | No | ICD-10 | Non-inpatient | 548 | NA | NA | I | 7 |
| Wu ( | 2011.9–2014.12 | Liaocheng, Shandong | CS | No | No | ICD-10 | Inpatient | 158 | 112 | 33.87 | II, III | 5 |
| Li ( | 2011.1–2011.12 | Zhenjiang, Jiangsu | CS | No | Yes | CCMD-3 | Inpatient | 138 | 74 | NA | II | 5 |
| Qiao and Di ( | NA | Lanzhou, Gansu | CS | No | No | CCMD-3 | Non-inpatient | 3,945 | NA | NA | I | 7 |
| Zheng ( | 2008.1–2014.1 | Nanning, Guangxi | CS | No | No | CCMD-3 | Inpatient | 1,283 | NA | NA | I | 7 |
| Hu and He ( | 2014.3–2016.3 | Wuhan, Hubei | CS | No | No | ICD-10 | Non-inpatient | 571 | NA | NA | I | 5 |
| Yu et al. ( | 2010.1 | Shaoxing, Zhejiang | CS | Yes | Yes | CCMD-3 | Non-inpatient | 766 | NA | NA | I | 7 |
| Ding et al. ( | 2016.12 | Beijing | CS | No | Yes | CCMD-3 | Non-inpatient | 1,740 | NA | NA | I | 7 |
| Yuan et al. ( | 2008.1–2017.12 | Yichang, Hubei | CS | No | No | ICD-10 | inpatient | 587 | NA | NA | III | 7 |
| Huang et al. ( | 2008.1–2014.12 | Nanning, Guangxi | CS | No | No | CCMD-3 | Non-inpatient | 1,637 | NA | NA | I | 7 |
| Yang et al. ( | 2018.3–2018.7 | Zhanjiang, Guangzhou | CS | Yes | No | ICD-10 | Inpatient | 226 | 116 | 35.12 | I | 7 |
| Wang et al. ( | NA | Gaoxiong, Taiwan | CS | Yes | NA | DSM-IV | Inpatient | 33 | 16 | 49.50 | I | 7 |
| Sun and Zhou ( | 2018.10–2019.10 | Xinxiang, Henan | CS | No | No | ICD-10 | Inpatient | 84 | 46 | NA | I, II, III | 5 |
| Li et al. ( | 2017.1–2019.12 | Wuxi, Jiangsu | CS | No | Yes | CCMD-3 | Non-inpatient | 15,233 | NA | NA | I | 7 |
| Chen et al. ( | 2018.10–2019.8 | Gaoxiong, Taiwan | CS | Yes | NA | DSM-V | Non-inpatient | 78 | 28 | 42.59 | II | 7 |
| Zhao ( | 2016.12–2019.12 | Liaoyang, Liaoning | CS | No | No | CCMD-3 | Inpatient | 201 | 125 | 36.02 | III | 7 |
| Sun et al. ( | NA | NA | CS | NA | NA | DSM-III | Non-inpatient | 7711 | 4491 | NA | III | 7 |
| Li ( | 2013.01–2020.01 | Yangjiang, Guangdong | CS | Yes | No | CCMD-3 | Inpatient | 1180 | NA | NA | I | 5 |
| Hu et al. ( | 2021.01–2021.12 | Ali, Tibet | CS | No | No | ICD-10 | Non-inpatient | 59 | NA | NA | II | 5 |
| Liang et al. ( | 2016.03–2019.10 | Hainan | CS | Yes | No | CCMD-3 | non-inpatient | 98 | NA | NA | I | 5 |
| Long et al. ( | 2019.03–2019.09 | Changsha, Hunan | CS | No | No | CCMD-3 | Non-inpatient | 400 | 200 | 46.87 | III | 7 |
| Pan et al. ( | 2019.04–2019.07 | Beijing | CS | No | Yes | ICD-10 | Non-inpatient | 2,100 | 940 | 39.80 | I | 7 |
| Yu et al. ( | 2021.03–2021.08 | Hefei, Anhui | CS | No | No | DSM-V | Inpatient | 397 | 397 | 39.86 | III | 7 |
*NA, Not Available; C, Cohort study; CS, Cross-Section study.
†We used the baseline data in these two studies.
Pooled estimate of prevalence of violence.
| Eligible studies | High-quality studies | |||||||||
| Type of violence | Number of data points | Pooled prevalence (%, 95% CI) |
| Number of data points | Pooled prevalence (%, 95% CI) |
| ||||
| I | 35 | 26.44 (20.62–32.68) | 7317.23 | <0.01 | 99.50 | 24 | 23.83 (18.38–29.75) | 3579.51 | <0.01 | 99.40 |
| II | 14 | 31.17 (21.70–41.49) | 284.46 | <0.01 | 95.40 | 5 | 23.16 (8.04–42.97) | 126.59 | <0.01 | 96.80 |
| III | 17 | 16.21 (9.57–24.16) | 1257.77 | <0.01 | 98.70 | 11 | 17.19 (8.52–28.04) | 1117.84 | <0.01 | 99.10 |
| Iv | 4 | 2.33 (0.31–5.90) | 33.05 | <0.01 | 90.90 | 2 | 0.62 (0.08–1.54) | 1.72 | 0.19 | 41.90 |
FIGURE 2Forest plot of the prevalence of violence. (A) Results of type I. (B) Results of type II. (C) Results of type III. (D) Results of type IV.
FIGURE 3Regional distribution for prevalence of violence. (A) Results of type I. (B) Results of type II. (C) Results of type III. (D) Results of type IV.
The results of multivariate meta-regression analysis (high-quality studies).
| Type of violence | Moderators | Number of data points | Coefficient (β) | Coefficient | |
| I | Patient source (inpatient/non-inpatient) | 20 | 0.15 | <0.01 | 42.03 |
| Total burden coefficient | 0.60 | 0.13 | |||
| II | Patient source (inpatient/non-inpatient) | 5 | 0.47 | <0.01 | 99.23 |
| Proportion of male patients (≤ 0.5/ > 0.5) | 0.19 | <0.01 | |||
| III | Age (≤ 40/ > 40) | 6 | 0.25 | <0.01 | 87.40 |
| GDP per capita ($10,000) | 0.05 | 0.01 |